Ligand Partner Travere Receives FDA Approval for Filspari
Ligand (LGND) announced that its partner Travere Therapeutics (TVTX) has received approval from the FDA for Filspari to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis without nephrotic syndrome.
